Top

Jonathan M. Kurie, MD

Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine

About Dr. Jonathan M. Kurie

The current research of the Kurie Laboratory is centered on the investigation of mechanisms of lung cancer metastasis for the purpose of identifying novel therapeutic targets. Of foremost interest is to understand how the cellular and extracellular matrix constituents of the tumor microenvironment are controlled by tumor cells, and how signals from the microenvironment influence tumor cell behavior. In this effort, the Kurie lab uses cellular models, genetic mouse models of lung cancer that recapitulate key somatic genetic mutations and epigenetic events in tumor cells, and a tissue bank of molecularly and clinically annotated human lung cancers and matched normal lung. Dr. Kurie has been mentoring postdoctoral fellows, graduate students, and technicians, and has received the Mentor of the Year Award at MD Anderson in 2012. He has been actively involved in the career development of several researchers, some of whom have gone on to establish them self as independent investigators and physician scientists.

Primary Appointment

Endowed Professor Gloria Lupton Tennison Distinguished Professorship in Lung Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

The primary focus of my laboratory is to elucidate how extracellular signals govern tumor cell metastatic activity. To address this question, we have created murine and cellular models of human lung cancer in which tumor cells and collagenous stroma can be visualized microscopically in 3 dimensions and in real time. We have shown that tumor cells gain metastatic properties by inducing the formation of a particularly stable type of collagen cross-link driven by high expression of lysyl hydroxylase 2 (LH2), a collagen lysyl hydroxylase. We have shown that this enzyme is secreted and modifies both intracellular nascent collagen strands and extracellular triple helical collagen molecules, and that LH2-driven cross-links enhance the migratory and invasive properties of tumor cells. We have identified small molecule inhibitors of LH2 from high throughput screens and are currently generating LH2 crystal structures for the purpose of molecular modeling to generate antagonists with improved potency and selectivity. This project offers Medical Oncology fellows an opportunity to gain expertise in microscopy, tumor cell biology, and collagen biochemistry in a novel field with strong translational potential.

Education & Training

Degree-Granting Education

1983	East Carolina University, Greenville, North Carolina, US, MD
1979	University of North Carolina, Chapel Hill, North Carolina, US, Chemistry, BA

Postgraduate Training

1988-1993	Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center, New York, New York
1986-1988	Biotechnology Fellow, Laboratory of Genetics, National Institutes of Health, National Cancer Institute, Bethesda, Maryland
1984-1986	Resident, Medical College of Georgia, Augusta, Georgia
1983-1984	Intern, Medical College of Georgia, Augusta, Georgia

Licenses & Certifications

1993	Texas State Board of Medical Examiners
1991	Medical Oncology Subspecialty
1986	American Board of Internal Medicine

Experience & Service

Faculty Academic Appointments

Elza and Ina Shackelford Freeman Endowed Professorship, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2019

Associate Internist and Associate Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2004

Assistant Internist and Assistant Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993 - 1999

Instructor, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 1992 - 1993

Other Professional Positions

Member, Landon Foundation-AACR Innovator Award for Cancer Prevention Research Scientific Review Committee, Houston, TX, 2013 - 2014

Steering Committee Member, Mouse Models of Human Cancer Consortium, National Cancer Institute, Bethesda, MD, 1998 - 2009

Extramural Institutional Committee Activities

Member, MD Anderson 2021-9 Research Integrity Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Co-Chair, MD Anderson Sabin Fellows Review Panel, The University of Texas MD Anderson Cancer Center, 2014 - Present

Faculty and Mentor, T32 Training Program, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Research Faculty Hiring Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Co-Director, Physician Scientists Award Steering Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Member, ASCO YIA Oversight Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Bridge Funding Advisory Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Chair, Laboratory Space Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2012

Member, Multi-disciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2012

Member, Laboratory Space Subcommittee, The University of Texas MD Anderson Cancer Center, 2004 - 2008

Member, Search Committee for Lymphoma/Myeloma Department Chairman, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Member, Research Subcommittee, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2001 - 2003

Member, Joint Steering Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, GSBS Cancer Biology Program, The University of Texas MD Anderson Cancer Center, 1998 - 2006

Member, Utilization Management Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1995

Member, Nutritional Support Service, The University of Texas MD Anderson Cancer Center, 1994 - 1996

Alternate Member, Infectious Disease Control Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1996

Editorial Activities

Senior Editor, Cancer Prevention Research, 2007 - 2011

Associate Editor, Cancer Research, 2005 - 2013

Honors & Awards

2019 - 2024	Gloria Lupton Tennison Distinguished Professorship in Lung Cancer Research, The University of Texas MD Anderson Cancer Center
2018	Robert M. Chamberlain Distinguished Mentor Award, Finalist, University of Texas MD Anderson Cancer Center
2017	Waun Ki Hong Award for Excellence in Team Science, The University of Texas MD Anderson Cancer Center
2013	The Julie and Ben Rogers Award of Excellence in Research Finalist, The University of Texas MD Anderson Cancer Center
2012	Potu N. Rao Award for Excellence in Basic Science, The University of Texas MD Anderson Cancer Center
2012	The MDACC Division of Cancer Medicine Mentor of the Year Award, The University of Texas MD Anderson Cancer Center
2007 - 2019	Elza and Ina Shackleford Freeman Endowed Professor in Lung Cancer, The University of Texas MD Anderson Cancer Center
2005	Elkins Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center
2005	Margaret and James A. Elkins Faculty Achievement Award in Cancer Prevention
2001	American Society for Clinical Investigation
1999 - 2001	Sidney Kimmel Scholar Award
1995	Physicians Referral Service Award, The University of Texas MD Anderson Cancer Center
1994	American Cancer Society Career Development Award (relinquished because R29)
1993	University Cancer Foundation Award, The University of Texas MD Anderson Cancer Center
1992	Schering Corporation ASCO Travel Award
1990 - 1993	National Research Service Award, National Institutes of Health
1983	Department of Pathology Scholarship Award, East Carolina University
1978	Academic Dean's List, University of North Carolina

Professional Memberships

Endowed Positions & Awards Committee (EPAC)

2016 - Present

Faculty Promotions and Tenure Advisory Council

2015 - Present

Thoracic and Cardiovascular Surgery Chair Search Committee

2014 - Present

American Association for Cancer Research

2012

Medical Oncology Subspecialty, ABIM (renewed 07/2011)

1991

American Board of Internal Medicine

1986

Selected Presentations & Talks

Formal Peers

2019. The Epithelial-to-Mesenchymal Transition in Cancer Metastasis. Invited. Los Angeles, CA, US.
2018. Distinguished Lectures in Cancer Research Series. Invited. Philadelphia, PA, US.
2015. Transcriptional control of Golgi functions in tumor cells drives EMT and metastasis. Invited. New York, NY, US.
2014. Mechanisms of Lung Cancer Metastasis. Invited. New York, NY, US.
2014. Zeb1 as a Driver of Lung Cancer Metastasis. Invited. Rochester, MN, US.
2014. A Novel Regulator of Collagen Cross-linking, Tumor Stiffness and Metastasis. Invited. Rochester, MN, US.
2014. Mechanisms of Lung Cancer Metastasis. Invited. Detroit, MI, US.
2013. Mechanisms of Lung Cancer Metastasis. Invited. Portland, OR, US.
2013. Mechanisms of Lung Cancer Metastasis. Invited. Columbus, OH, US.
2013. Mechanisms of Lung Cancer Metastasis. Invited. Dallas, TX, US.
2013. Mechanisms of Lung Cancer Metastasis. Invited. Durham, NC, US.
2013. Mechanisms of Lung Cancer Metastasis. Invited. Houston, TX, US.
2012. Cancer Research UK Lung Cancer Symposium. Invited. Manchester, London, GB.
2011. Chemoprevention, Lung Neoplasms. Visiting. Houston, TX, US.
2011. Regulation of mir200 and its Target Genes in Lung Cancer. Visiting. Houston, TX, US.
2011. Mechanisms of Lung Cancer Metastasis. Visiting. Nashville, TN, US.
2011. Lung Cancer, Tumor Microenvironment. Invited. Houston, TX, US.
2011. ICC on Metastasis and Angiogenesis. Invited. Barcelona, ES.
2010. New Insights into Lung Cancer Metastasis. Invited. Tampa, FL, US.
2010. Mechanisms of Lung Cancer Metastasis. Visiting. Houston, TX, US.
2009. The Notch Ligand Jagged2 Promotes Metastasis through a GATA3/miR-200 Regulatory Loop. Invited. Vienna, VA, US.
2008. Stem Cells in Mouse Models of K-ras Induced Lung Cancer. Invited. Pearl River, NY, US.
2008. Mouse Models of Lung Cancer. Invited. Raleigh Durham, NC, US.
2008. Genetic Mouse Models of Lung Cancer. Invited. Philadelphia, PA, US.
2008. Novel Therapies. Invited. Las Vegas, NV, US.
2007. The Role of the Tumor Microenvironment in Lung Cancer. Invited. Danvers, MA, US.
2007. Lung Cancer in Humans. Invited. Bar Harbor, ME, US.
2007. Role of Tumor Microenvironment in the Production of Alveolar Epithelial Neoplasia Induced by Oncogenic KRAS. Invited. Palm Beach, FL, US.
2006. Creation of Mouse Models of Human Lung Cancer by Activation of P13K/AKT-dependent Signaling NCI Mouse. Invited. Seattle, WA, US.
2006. Targeting Kinases in Lung Cancer Prevention and Treatment. Visiting. Houston, TX, US.
2005. Targeting Kinases Pathways in Lung Cancer Prevention and Therapy. Invited. Tampa, FL, US.
2004. Early Diagnosis and Chemoprevention of Lung Cancer: New Molecular Approaches. Invited. Los Angeles, CA, US.
2004. Kinase Pathways as Targets in Lung Cancer Prevention and Therapy. Visiting. Minneapolis, MN, US.
2004. Stress Contributes to Aberrant Retinoid Signaling in Lung Cancer Cells through cJun N-Terminal Kinase, which Phosphorylates and Induces Proteasomal Degradation of Retinoic Acid Receptor-alpha. Invited. Pine Mountain, GA, US.
2004. Targeting Kinases in Lung Cancer Prevention and Treatment. Invited. San Diego, CA, US.
2003. Retinoid-based Lung Cancer Prevention Trial in Former Smokers. Invited. Bethesda, MD, US.
2003. Targeting Kinases in Lung Cancer Prevention and Therapy. Invited. San Diego, CA, US.
2003. Targeting PI3K-dependent Signaling in Lung Cancer Prevention and Therapy. Invited. Aspen, CO, US.
2003. Targeting Kinases in Lung Cancer Prevention and Therapy. Invited. Charlottesville, VA, US.
2002. Oncology Consultants Meeting. Invited. Palm Beach, FL, US.
2002. Kinase Pathways as Targets in Lung Cancer Therapy and Prevention. Invited. Albuquerque, NM, US.
2002. Targeting Kinases in Lung Cancer Prevention Therapy. Invited. San Francisco, CA, US.
2002. Targeting Kinases in Lung Cancer Prevention Therapy. Invited. Montreal, CA.
2002. Clinical Trial of Celecoxib in the Lung Cancer Chemoprevention. Invited. Scottsdale, AZ, US.
2002. Targeting Kinase in Lung Cancer Prevention Therapy. Invited. New York City, NY, US.
2002. Lung Cancer Therapeutics and Prevention: State of the Art and Future Challenges. Invited. Bethesda, MD, US.
2002. Clinical Therapeutics. Invited. Bethesda, MD, US.
2001. Targeting Kinases in Lung Cancer Prevention Therapy. Invited. Omaha, NE, US.
2001. Targeting Kinases in Lung Cancer Prevention and Therapy. Visiting. Houston, TX, US.
2001. Growth Regulatory Pathways in Lung Cancer. Invited. Manchester, NH, US.
2001. MAP Kinases as Targets in Lung Cancer Chemoprevention. Invited. Boston, MA, US.
2001. Chemoprevention in Individuals at Risk for Lung Cancer. Invited. Buffalo, NY, US.
2001. Role of IGFBP-6 in Human Bronchial Epithelial Cells and Lung Cancer Cells. Invited. Research Triangle Park, NC, US.
2001. Gene Delivery to Lung Tumors by Aerosolization of Adenovirus Incorporated into Calcium Phosphate Precipitates. Invited. Houston, TX, US.
2001. MAP Kinases in Retinoid Response and Resistance. Invited. Los Angeles, CA, US.
1999. Retinoids in Lung Cancer Prevention, Grand Rounds. Invited. Buffalo, NY, US.
1999. Retinoids in Lung Cancer Prevention. Visiting. Houston, TX, US.
1997. Retinoid Signaling in Human Bronchial Epithelial Cells. Visiting. Houston, TX, US.

Less

Grant & Contract Support

Date:	2026 - 2029
Title:	Targeted therapeutic intervention of minimal residual disease in EGFRm non-small cell lung cancer to enhance cures by preventing resistance and histologic transformation
Funding Source:	LCRF
Role:	Key
ID:	FP00028346

Date:	2025 - 2029
Title:	Targeting the Golgi to Inhibit Lung Cancer Metastasis
Funding Source:	American Cancer Society
Role:	Co-PI
ID:	FP00024297

Date:	2025 - 2030
Title:	Non oncogene addiction and synthetic lethality in lung cancer
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	GRANT14222933

Date:	2024 - 2031
Title:	Defining and defeating hypersecretory states in lung cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00020688

Date:	2023 - 2028
Title:	MD Anderson SPORE in KRASG12C
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	P50CA281788

Date:	2022 - 2027
Title:	An EMT-activated vesicular trafficking program that drives focal adhesion dynamics and a pro-metastatic secretory process in lung adenocarcinoma
Funding Source:	NIH/NCI
Role:	PI
ID:	PA-20-185

Date:	2021 - 2026
Title:	Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00013089

Date:	2021 - 2023
Title:	A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	K99CA249048-01

Date:	2021 - 2026
Title:	A pro-metastatic secretory pathway activated by p53 loss in lung cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA255021-01/GRANT13217724

Date:	2021 - 2026
Title:	Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA251067-01

Date:	2021 - 2026
Title:	Transcriptional control of pro-metastatic vesicular trafficking in lung cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 PA-20-185/GRANT13100508

Date:	2020 - 2025
Title:	A pro-metastatic secretory pathway activated by p53 mutations in lung cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA255021

Date:	2020 - 2025
Title:	SPORE: Targeting Lung Cancer Vulnerabilities; Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers
Funding Source:	NIH/NCI
Role:	Co-Project Leader
ID:	P50CA070907-21

Date:	2020 - 2024
Title:	Targeting Lung Cancer Vulnerabilities - Project 3: Targeting the fibrotic extracellular matrix (ECM) of lung tumors to enhance immune surveillance, suppress metastasis and improve checkpoint inhibitor therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2P50CA070907-21 (Renewal)

Date:	2020 - 2025
Title:	ZEB1 is a nodal factor that coordinates inter-organelle communication during epithelial-to-mesenchymal transition in cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	PAR 17-203/GRANT12911977

Date:	2020 - 2025
Title:	Targeting tankyrase to modulate the LKB1/AMPK pathway to block tumorigenesis and mitigate therapy resistance
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	GRANT12893746

Date:	2019 - 2024
Title:	Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA236781-02

Date:	2019 - 2020
Title:	UT SPORE: Developing New Rationale, personalized Medicine for Lung cancer Project 3: Targeting the Tumor Microenvironment in NSCLC
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5P50CA70907-20

Date:	2019 - 2024
Title:	Cell-free DNA (cfDNA) to detect minimal residual disease, predict therapeutic response, and characterize immunogenomic evolution in early-stage NSCLC treated with neoadjuvant immunotherapy
Funding Source:	NIH/NCI
Role:	PI
ID:	GRANT12717352

Date:	2018 - 2023
Title:	Regulation of lung cancer metastasis by cancer-associated fibroblasts
Funding Source:	NIH/NCI
Role:	PI
ID:	GRANT12552888

Date:	2018 - 2020
Title:	Targeting chromosome 1q21.3–amplified lung cancer using PI4KB antagonists
Funding Source:	Lung Cancer Research Foundation
Role:	Mentor

Date:	2018 - 2020
Title:	Study of the effects of EMT-driven interactions between tumor cells and cancer associated fibroblasts during lung cancer metastasis
Funding Source:	Lung Cancer Research Foundation
Role:	Mentor

Date:	2018 - 2020
Title:	Determining structural features of a collagen lysyl hydroxylase that promotes lung cancer metastasis
Funding Source:	NIH/NCI
Role:	Mentor
ID:	K99CA225633-01A1

Date:	2018 - 2021
Title:	Targeting Anaphase Catastrophe
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01CA190722-05

Date:	2018 - 2023
Title:	Development of pharmacologic strategies and mouse models to study the pro-metastatic role of lysyl hydroxylase 2 in lung cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	PAR-16-160

Date:	2017 - 2022
Title:	Cellular Natural Matrix Model to Study Mechanism of Formation of Circulating Tumor Cells
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PAR-16-105

Date:	2017 - 2018
Title:	SAXS-based crystallography of lysyl hydroxylase 2, a metastasis driver in KRAS-mutant lung cancer
Funding Source:	Jane-Ford Petrin Fund
Role:	PI

Date:	2016 - 2022
Title:	Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA211125-05

Date:	2016 - 2018
Title:	The regulation of LH2 function in Lung cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA208926-01

Date:	2016 - 2022
Title:	Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers - Project 4: Exploring lysyl hydroxylase 2 (LH2) as a pharmacologically actionable metastasis driver in KRAS-mutant lung cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160652 - P4

Date:	2016 - 2022
Title:	Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers - Administrative Core
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160652 - AC

Date:	2015 - 2020
Title:	Defining and Defeating Mechanistic Subtypes
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP150519

Date:	2015 - 2020
Title:	The Role of PLOD2 Pathway in Lung Cancer Progression and Metastasis
Funding Source:	NIH/NCI
Role:	Primary Mentor
ID:	1K99CA193663-01

Date:	2015 - 2018
Title:	Pericytic Origins and Functions of Cancer-Associated Fibroblasts
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP150095

Date:	2014 - 2020
Title:	Regulation of Lung Cancer Metastasis by ZEB1
Funding Source:	NIH/NCI
Role:	PI
ID:	1-R01-CA181184-01A1

Date:	2014 - 2019
Title:	Targeting the Tumor Microenvironment in NSCLC
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5-P50-CA70907-16 PP-3 - Project 4

Date:	2014 - 2019
Title:	Genetic Variants in Epithelial Mesenchymal Transition (EMT) Pathway in Non-small Cell Lung Cancer: Prognosis, Mechanism, and Therapeutic Application
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	U01-CA187920-01

Date:	2014 - 2018
Title:	(PQB6) Modeling the Extracellular Matrix of Metastatic Lung Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA296038-01

Date:	2014 - 2014
Title:	Bridge Funding - Regulation of Lung Cancer Metastasis by a Pro-collagen Lysyl Hydroxylase
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI
ID:	2-R01-CA132608-06

Date:	2014 - 2024
Title:	SPORE Grant - Preclinical Development and Clinical Testing of MEK and PI3K Targeted Therapy for KRAS-mutant NSCLC as a Method of Radiosensitization and Metastasis Inhibition
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5-P50-CA70907-16 PP-3

Date:	2013 - 2014
Title:	LH2-driven Collagen Cross-linking as a Novel Mediator of Lung Cancer Metastasis
Funding Source:	Lung Cancer Research Foundation
Role:	PI

Date:	2013 - 2014
Title:	Year 15 Extension for UT Lung SPORE
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Project Leader

Date:	2013 - 2014
Title:	UT Lung SPORE Supplement, Project 3: Targeting the Tumor Microenvironment in NSCLC
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5-P50-CA70907-15 PP-3

Date:	2013 - 2014
Title:	Bridge Funding Award for UT Lung SPORE
Funding Source:	University of Texas MD Anderson Cancer Center
Role:	Project Leader

Date:	2012 - 2018
Title:	Integrative Analysis of the Lung Cancer Microenvironment
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT): Multi-investigator Research Award (MIRA)
Role:	PI
ID:	RP120713-AC

Date:	2012 - 2018
Title:	Cancer-associated Fibroblasts in Lung Cancer Invasion
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT): Multi-investigator Research Award (MIRA)
Role:	PI
ID:	RP120713-PI

Date:	2012 - 2017
Title:	Discovery of CAF-derived Factors that Promote Tumor Cell Invasion and Metastasis
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01-CA173213-01

Date:	2012 - 2017
Title:	Pro-metastatic Genes that Induce CD8+ T Cell Anergy and Tumor Cell Invasion
Funding Source:	NIH/NCI
Role:	PI

Date:	2011 - 2016
Title:	Regulation of Lung Cancer Metastasis by miR-200
Funding Source:	NIH/NCI
Role:	PI
ID:	1-R01-CA157450-03

Date:	2009 - 2011
Title:	Role of the Scribble Polarity Complex in Lung Cancer Invasion and Metastasis
Funding Source:	Howard Hughes Medical Institute (HHMI)
Role:	Principal Investigator and Mentor for Zain Rizvi, whose stipend was supported by this training grant
ID:	HHMI 02

Date:	2009 - 2011
Title:	The Role of the MicroRNA-200 Family in Lung Cancer Epithelial-mesencymal Transition and Metastasis
Funding Source:	International Association for the Study of Lung Cancer
Role:	PI
ID:	IASLC 02

Date:	2008 - 2011
Title:	Development of Mouse models to Study Lung Cancer Adrenal Metastasis
Funding Source:	Cohen-Reinach Family Charitable Foundation
Role:	Co-I
ID:	BATTLE II (PC-E)

Date:	2008 - 2013
Title:	Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis
Funding Source:	NIH/NCI
Role:	PI
ID:	5-R01-CA132608-03

Date:	2007 - 2012
Title:	Tumor and PTK-targeted Therapy by FUS1 and PTK Inhibitors
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5R01 CA116322

Date:	2006 - 2012
Title:	Mediators of Oncogenic KRAS in Lung Adenocarcinoma
Funding Source:	NIH/NCI
Role:	PI
ID:	5-R01-CA117965-05

Date:	2006 - 2009
Title:	Research Training in Academic Medical Oncology
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2-T32-CA009666-12

Date:	2005 - 2016
Title:	The Role of Endothelial CXCR2 in Lung Adenocarcinoma Angiogenesis and Metastasis
Funding Source:	NIH/NCI
Role:	PI
ID:	2-R01-CA117965-06

Date:	2004 - 2010
Title:	Modeling Airway Lung Cancer and the Role of Inflammation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5-U01-CA105352-05

Date:	2004 - 2019
Title:	Regulation of Lung Cancer Metastasis by a Pro-collagen Lysyl Hydroxylase
Funding Source:	NIH/NCI
Role:	PI
ID:	2-R01-CA105155-11A1

Date:	2004 - 2014
Title:	Kinase Signaling in Lung Tumorigenesis
Funding Source:	NIH/NCI
Role:	PI
ID:	5-R01-CA105155-10

Date:	2004 - 2021
Title:	Regulation of Lung Cancer Metastasis by a Pro-collagen Lysyl Hydroxylase
Funding Source:	NIH/NCI
Role:	PI
ID:	2R01CA10515511-15

Date:	2002 - 2008
Title:	The P13K Pathway as a Target for Lung Cancer Prevention and Therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	P50-CA70907

Date:	2001 - 2006
Title:	Clinical Trial of Celecoxib in Lung Cancer Chemoprevention
Funding Source:	NIH/NCI
Role:	PI
ID:	P01-CA91844-1

Date:	2001 - 2007
Title:	IGFBP-6: A Target in Lung Cancer Prevention
Funding Source:	NIH/NCI
Role:	PI
ID:	5-R01-CA91727-06

Date:	2000 - 2003
Title:	Genomic Evaluation of In Vivo and in Vitro Pharmacology and Toxicology of Preventive Agents Using Human Mutant Cells from Dominantly Heritable Cancers: Li Fraumeni syndrome and Bilateral Retinoblastoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	N01-CN-05023-39

Date:	2000 - 2006
Title:	Retinoid Signaling in New Lung Cancer Prevention Models
Funding Source:	NIH/NCI
Role:	PI
ID:	1-R01-CA080686-01A1

Date:	2000 - 2002
Title:	Lung Cancer Chemoprevention by Deguelin, a COX-2 Inhibitor
Funding Source:	Mammalian Cancer Models SPORE Supplement
Role:	Co-I
ID:	P50CA70907

Date:	1999 - 2009
Title:	Role of EGFR in Lung Tumorigenesis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5-U01-CA84306-07

Date:	1999 - 2001
Title:	Ras-dependent Pathways as Mediators of Retinoid-induced Lung Cancer Chemoprevention
Funding Source:	Sidney Kimmel Scholar Award
Role:	PI

Date:	1998 - 1999
Title:	Ras-dependent Pathways as Mediators of Retinoid-induced Lung Cancer Chemoprevention
Funding Source:	Developmental Award, Lung Cancer SPORE Grant
Role:	PI

Date:	1998 - 2001
Title:	Role of AP-1 in Retinoid Sensitivity and Resistance
Funding Source:	American Cancer Society
Role:	PI
ID:	RPG-98-189-CNE

Date:	1998 - 2004
Title:	Retinoid Prevention of Lung Cancer in Former Smokers
Funding Source:	Lung Cancer SPORE Grant
Role:	PI
ID:	P50CA70907

Date:	1995 - 2001
Title:	Retinoid Signaling in Human Bronchial Epithelial Cells
Funding Source:	NIH FIRST Award
Role:	PI
ID:	R29 CA 67353

Date:	1995 - 1996
Title:	Mechanisms of Lung Cancer Chemoprevention by Retinoid Treatment
Funding Source:	The University of Texas M. D. Anderson Cancer Center
Role:	PI

Date:	1994 - 1997
Title:	The Role of Retinoids in Lung Cancer Chemoprevention
Funding Source:	American Cancer Society
Role:	PI

Date:	1994 - 1995
Title:	The Role of Retinoids in Lung Cancer Chemoprevention
Funding Source:	The University of Texas M. D. Anderson Cancer Center
Role:	Principal Investigator-MDACC

Date:	1990 - 1993
Title:	Role of FOS, Jun, and RAS in RA-induced TC Differentiation
Funding Source:	NIH National Research Service Award
Role:	PI
ID:	#F32 CA08940

Selected Publications

Peer-Reviewed Articles

Ghosh M, Wu C, Kumar A, Nilsson MB, Heymach JV, Zhao W, Yu J, Liu X, Ding N, Wang S, Xiao GY, Chen A, Grimley KV, Russell WK, Creighton CJ, Tan X, Kurie JM. Osimertinib activates a TGFbeta2-dependent secretory program that drives lung adenocarcinoma progression. J Clin Invest, 2025. e-Pub 2025. PMID: 41364502.
Lee, S, Park, J, Cho, S, Kim, E, Oh, S, Lee, Y, Park, S, Kang, K, Shin, DH, Ko, SY, Kurie, JM, Ahn, YH. Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells. Journal of Clinical Investigation 135(11), 2025. e-Pub 2025. PMID: 40178908.
Cai, L, Wu, F, Zhou, Q, Gao, Y, Yao, B, Deberardinis, RJ, Acquaah-Mensah, G, Aidinis, V, Beane, J, Biswal, S, Chen, T, Concepcion-Crisol, CP, Grüner, BM, Jia, D, Jones, RA, Kurie, JM, Lee, MG, Lindahl, P, Lissanu, Y, Lorz, C, MacPherson, D, Martinelli, R, Mazur, PK, Mazzilli, SA, Mii, S, Moll, HP, Moorehead, RA, Morrisey, EE, Ng, SR, Oser, M, Pandiri, AR, Powell, CA, Ramadori, G, Santos, M, Snyder, EL, Sotillo, R, Su, KY, Taki, T, Taparra, K, Tran, PT, Xia, Y, Van Veen, JE, Winslow, MM, Xiao, G, Rudin, CM, Oliver, TG, Xie, Y, Minna, J. The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models. Cancer Research 85(10):1769-1783, 2025. e-Pub 2025. PMID: 40298430.
Wang S, Guo H, Fukushima R, Terajima M, Liu M, Xiao GY, Koudelkova L, Wu C, Liu X, Yu J, Burris E, Xu J, Schiavinato A, Russell WK, Yamauchi M, Tan X, Kurie JM. Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression. J Clin Invest 135(7), 2025. e-Pub 2025. PMID: 40166934.
Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
Cai L, Gao Y, DeBerardinis RJ, Acquaah-Mensah G, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Gruner BM, Jia D, Jones R, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz Lopez MC, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll H, Moorehead R, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos Lafuente M, Snyder E, Sotillo R, Su KY, Taki T, Taparra K, Xia Y, van Veen E, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna JD. A Lung Cancer Mouse Model Database. bioRxiv, 2024. e-Pub 2024. PMID: 38464291.
Tan X, Wang S, Xiao GY, Wu C, Liu X, Zhou B, Jiang Y, Duose DY, Xi Y, Wang J, Gupta K, Pataer A, Roth JA, Kim MP, Chen F, Creighton CJ, Russell WK, Kurie JM. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer. J Clin Invest 134(12), 2024. e-Pub 2024. PMID: 38662435.
Lee J, Guo HF, Wang S, Maghsoud Y, Vázquez-Montelongo EA, Jing Z, Sammons RM, Cho EJ, Ren P, Cisneros GA, Kurie JM, Dalby KN. Unleashing the Potential of 1,3-Diketone Analogues as Selective LH2 Inhibitors. ACS Med Chem Lett 14(10):1396-1403, 2023. e-Pub 2023. PMID: 37849534.
Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A 120(28):e2220276120, 2023. e-Pub 2023. PMID: 37406091.
Tan X, Xiao GY, Wang S, Shi L, Zhao Y, Liu X, Yu J, Russell WK, Creighton CJ, Kurie JM. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. J Clin Invest 133(7), 2023. e-Pub 2023. PMID: 36757799.
Maghsoud Y, Vázquez-Montelongo EA, Yang X, Liu C, Jing Z, Lee J, Harger M, Smith AK, Espinoza M, Guo HF, Kurie JM, Dalby KN, Ren P, Cisneros GA. Computational Investigation of a Series of Small Molecules as Potential Compounds for Lysyl Hydroxylase-2 (LH2) Inhibition. J Chem Inf Model 63(3):986-1001, 2023. e-Pub 2023. PMID: 36779232.
Banerjee P, Tan X, Russell WK, Kurie JM. Analysis of Golgi Secretory Functions in Cancer. Methods Mol Biol 2557:785-810, 2023. e-Pub 2023. PMID: 36512251.
Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio LM, Roszik J, Ferry-Galow KV, Parchment RE, Liu X, Andresson T, Duncan G, Kurie JM, Rodriguez-Canales J, Liu X, Dmitrovsky E. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis. Cancer Biol Ther 23(1):265-280, 2022. e-Pub 2022. PMID: 35387560.
Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
Terajima M, Taga Y, Nakamura T, Guo HF, Kayashima Y, Maeda-Smithies N, Parag-Sharma K, Kim JS, Amelio AL, Mizuno K, Kurie JM, Yamauchi M. Lysyl hydroxylase 2 mediated collagen post-translational modifications and functional outcomes. Sci Rep 12(1):14256, 2022. e-Pub 2022. PMID: 35995931.
Roszik J, Lee JJ, Wu YH, Liu X, Kawakami M, Kurie JM, Belouali A, Boca SM, Gupta S, Beckman RA, Madhavan S, Dmitrovsky E. Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival. Cancer Res Commun 2(7):590-601, 2022. e-Pub 2022. PMID: 35832288.
Kim EJ, Kim JS, Lee S, Cheon I, Kim SR, Ko YH, Kang K, Tan X, Kurie JM, Ahn YH. ZEB1-regulated lnc-Nr2f1 promotes the migration and invasion of lung adenocarcinoma cells. Cancer Lett 533:215601, 2022. e-Pub 2022. PMID: 35176421.
Tan X, Banerjee P, Liu X, Yu J, Lee S, Ahn YH, Creighton CJ, Kurie JM. Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis. JCI Insight 7(1), 2022. e-Pub 2022. PMID: 34874914.
Wilson AN, Chen B, Liu X, Kurie JM, Kim J. A Method for Orthotopic Transplantation of Lung Cancer in Mice. Methods Mol Biol 2374:231-242, 2022. e-Pub 2022. PMID: 34562257.
Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
Banerjee P, Xiao GY, Tan X, Zheng VJ, Shi L, Rabassedas MNB, Guo HF, Liu X, Yu J, Diao L, Wang J, Russell WK, Roszik J, Creighton CJ, Kurie JM. The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nat Commun 12(1):6354, 2021. e-Pub 2021. PMID: 34732702.
Shi L, Tan X, Liu X, Yu J, Bota-Rabassedas N, Niu Y, Luo J, Xi Y, Zong C, Creighton CJ, Glenn JS, Wang J, Kurie JM. Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells. Proc Natl Acad Sci U S A 118(25), 2021. e-Pub 2021. PMID: 34155143.
Tan X, Banerjee P, Shi L, Xiao GY, Rodriguez BL, Grzeskowiak CL, Liu X, Yu J, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. p53 loss activates pro-metastatic secretory vesicle biogenesis in the Golgi. Sci Adv 7(25), 2021. e-Pub 2021. PMID: 34144984.
Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep 35(3):109009, 2021. e-Pub 2021. PMID: 33882319.
Guo HF, Bota-Rabassedas N, Terajima M, Leticia Rodriguez B, Gibbons DL, Chen Y, Banerjee P, Tsai CL, Tan X, Liu X, Yu J, Tokmina-Roszyk M, Stawikowska R, Fields GB, Miller MD, Wang X, Lee J, Dalby KN, Creighton CJ, Phillips GN, Tainer JA, Yamauchi M, Kurie JM. A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. Commun Biol 4(1):482, 2021. e-Pub 2021. PMID: 33875777.
Liu X, Lu Y, Chen Z, Liu X, Hu W, Zheng L, Chen Y, Kurie JM, Shi M, Mustachio LM, Adresson T, Fox S, Roszik J, Kawakami M, Freemantle SJ, Dmitrovsky E. The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth. Mol Cancer Res 19(4):667-677, 2021. e-Pub 2021. PMID: 33380466.
Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X, Dmitrovsky E. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers. Mol Cancer Ther 20(3):477-489, 2021. e-Pub 2021. PMID: 33277443.
Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
Tan X, Shi L, Banerjee P, Liu X, Guo HF, Yu J, Bota-Rabassedas N, Rodriguez BL, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. A pro-tumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. J Clin Invest 131(1), 2021. e-Pub 2021. PMID: 32931483.
Bota-Rabassedas N, Guo HF, Banerjee P, Chen Y, Terajima M, Yamauchi M, Kurie JM. Use of osteoblast-derived matrix to assess the influence of collagen modifications on cancer cells. Matrix Biol Plus 8:100047, 2020. e-Pub 2020. PMID: 33543040.
Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol 91-92:8-18, 2020. e-Pub 2020. PMID: 32442601.
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med 12(527), 2020. e-Pub 2020. PMID: 31969487.
Dmitrovsky E, Kawakami M, Liu XI, Freemantle SJ, Kurie JM. TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS. Trans Am Clin Climatol Assoc 131:82-94, 2020. e-Pub 2020. PMID: 32675848.
Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behrens C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Threonine Tyrosine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Mol Cancer Ther 18(10):1775-1786, 2019. e-Pub 2019. PMID: 31358662.
Yu X, Zhang Y, Wu B, Kurie JM, Pertsemlidis A. The miR-195 Axis Regulates Chemoresistance through TUBB and Lung Cancer Progression through BIRC5. Mol Ther Oncolytics 14:288-298, 2019. e-Pub 2019. PMID: 31508486.
Devkota AK, Veloria JR, Guo HF, Kurie JM, Cho EJ, Dalby KN. Development of a High-Throughput Lysyl Hydroxylase (LH) Assay and Identification of Small-Molecule Inhibitors against LH2. SLAS Discov 24(4):2472555218817057, 2019. e-Pub 2019. PMID: 30589612.
Kim JS, Kim EJ, Lee S, Tan X, Liu X, Park S, Kang K, Yoon JS, Ko YH, Kurie JM, Ahn YH. MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas. Exp Mol Med 51(1):9, 2019. e-Pub 2019. PMID: 30700696.
Guo HF, Tsai CL, Terajima M, Tan X, Banerjee P, Miller MD, Liu X, Yu J, Byemerwa J, Alvarado S, Kaoud TS, Dalby KN, Bota-Rabassedas N, Chen Y, Yamauchi M, Tainer JA, Phillips GN, Kurie JM. Author Correction: Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9(1):2719, 2018. e-Pub 2018. PMID: 29988035.
Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128(7):3198, 2018. e-Pub 2018. PMID: 30108197.
Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128(4):1267-1282, 2018. e-Pub 2018. PMID: 29324442.
Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci U S A 115(8):1913-1918, 2018. e-Pub 2018. PMID: 29434041.
Guo HF, Tsai CL, Terajima M, Tan X, Banerjee P, Miller MD, Liu X, Yu J, Byemerwa J, Alvarado S, Kaoud TS, Dalby KN, Bota-Rabassedas N, Chen Y, Yamauchi M, Tainer JA, Phillips GN, Kurie JM. Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9(1):512, 2018. e-Pub 2018. PMID: 29410444.
Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther 16(10):2234-2245, 2017. e-Pub 2017. PMID: 28729401.
Kim JS, Kim EJ, Kim HS, Kurie JM, Ahn YH. MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing. Biochem Biophys Res Commun 491(2):337-342, 2017. e-Pub 2017. PMID: 28733031.
Schliekelman MJ, Creighton CJ, Baird BN, Chen Y, Banerjee P, Bota-Rabassedas N, Ahn YH, Roybal JD, Chen F, Zhang Y, Mishra DK, Kim MP, Liu X, Mino B, Villalobos P, Rodriguez-Canales J, Behrens C, Wistuba II, Hanash SM, Kurie JM. Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis. Sci Rep 7(1):6478, 2017. e-Pub 2017. PMID: 28744021.
Chen Y, Terajima M, Banerjee P, Guo H, Liu X, Yu J, Yamauchi M, Kurie JM. FKBP65-dependent peptidyl-prolyl isomerase activity potentiates the lysyl hydroxylase 2-driven collagen cross-link switch. Sci Rep 7:46021, 2017. e-Pub 2017. PMID: 28378777.
Guo HF, Cho EJ, Devkota AK, Chen Y, Russell W, Phillips GN, Yamauchi M, Dalby KN, Kurie JM. A scalable lysyl hydroxylase 2 expression system and luciferase-based enzymatic activity assay. Arch Biochem Biophys 618:45-51, 2017. e-Pub 2017. PMID: 28216326.
Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R, Lu Y, Kurie JM, Gibbons DL, Mills GB, Wistuba II, Creighton CJ. Multiplatform-based molecular subtypes of non-small cell lung cancer. Oncogene 36(10):1384-1393, 2017. e-Pub 2017. PMID: 27775076.
Tan X, Banerjee P, Guo HF, Ireland S, Pankova D, Ahn YH, Nikolaidis IM, Liu X, Zhao Y, Xue Y, Burns AR, Roybal J, Gibbons DL, Zal T, Creighton CJ, Ungar D, Wang Y, Kurie JM. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction through PAQR11. J Clin Invest 127(1):117-137, 2017. e-Pub 2017. PMID: 27869652.
Chen Y, Guo H, Terajima M, Banerjee P, Liu X, Yu J, Momin AA, Katayama H, Hanash SM, Burns AR, Fields GB, Yamauchi M, Kurie JM. Lysyl Hydroxylase 2 Is Secreted By Tumor Cells and Can Modify Collagen in the Extracellular Space. J Biol Chem 291(50):25799-25808, 2016. e-Pub 2016. PMID: 27803159.
Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A 113(25):6955-60, 2016. e-Pub 2016. PMID: 27274057.
Terajima M, Taga Y, Chen Y, Cabral WA, Hou-Fu G, Srisawasdi S, Nagasawa M, Sumida N, Hattori S, Kurie JM, Marini JC, Yamauchi M. Cyclophilin-B modulates collagen cross-linking by differentially affecting lysine hydroxylation in the helical and telopeptidyl domains of tendon type I collagen. J Biol Chem 291(18):9501-12, 2016. e-Pub 2016. PMID: 26934917.
Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, Wistuba II, Creighton CJ, Gibbons DL, Hicks JM, Dickinson ME, West JL, Grande-Allen KJ, Hanash SM, Yamauchi M, Kurie JM. Cancer-associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res 14(3):287-95, 2016. e-Pub 2016. PMID: 26631572.
Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 5(11):e1234570, 2016. e-Pub 2016. PMID: 27999749.
Mishra DK, Compean SD, Thrall MJ, Liu X, Massarelli E, Kurie JM, Kim MP. Human Lung Fibroblasts Inhibit Non-Small Cell Lung Cancer Metastasis in Ex Vivo 4D Model. Ann Thorac Surg 100(4):1167-74; discussion 1174, 2015. e-Pub 2015. PMID: 26233278.
Kim JS, Kurie JM, Ahn YH. BMP4 depletion by miR-200 inhibits tumorigenesis and metastasis of lung adenocarcinoma cells. Mol Cancer 14(1):173, 2015. e-Pub 2015. PMID: 26395571.
Chen Y, Terajima M, Yang Y, Sun L, Ahn YH, Pankova D, Puperi DS, Watanabe T, Kim MP, Blackmon SH, Rodriguez J, Liu H, Behrens C, Wistuba II, Minelli R, Scott KL, Sanchez-Adams J, Guilak F, Pati D, Thilaganathan N, Burns AR, Creighton CJ, Martinez ED, Zal T, Grande-Allen KJ, Yamauchi M, Kurie JM. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest 125(3):1147-62, 2015. e-Pub 2015. PMID: 25664850.
Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS One 10(4):e0122628, 2015. e-Pub 2015. PMID: 25897662.
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
Vishnoi M, Mishra DK, Thrall MJ, Kurie JM, Kim MP. Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin. J Thorac Cardiovasc Surg 148(3):1056-63; discussion 1063-4, 2014. e-Pub 2014. PMID: 25129597.
Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124(6):2696-708, 2014. e-Pub 2014.
Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie JM, Cadranel J, Wislez M. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int J Cancer 134(4):765-77, 2014. e-Pub 2014. PMID: 23913633.
Mishra DK, Creighton CJ, Zhang Y, Gibbons DL, Kurie JM, Kim MP. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. Int J Cancer 134(4):789-98, 2014. e-Pub 2014. PMID: 23934967.
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in lung cancer patients. Mol Cancer Ther 12(8):1545-55, 2013. e-Pub 2013. PMID: 23686769.
Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2013. PMID: 23204236.
Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res 5:187-95, 2013. e-Pub 2013. PMID: 23986650.
Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One 8(6):e67054, 2013. e-Pub 2013. PMID: 23785517.
Gill BJ, Gibbons DL, Roudsari LC, Saik JE, Rizvi ZH, Roybal JD, Kurie JM, West JL. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res 72(22):6013-23, 2012. e-Pub 2012. PMID: 22952217.
Schumacher MA, Min J, Link TM, Guan Z, Xu W, Ahn YH, Soderblom EJ, Kurie JM, Evdokimov A, Moseley MA, Lewis K, Brennan RG. Role of unusual P loop ejection and autophosphorylation in hipA-mediated persistence and multidrug tolerance. Cell Rep 2(3):518-25, 2012. e-Pub 2012. PMID: 22999936.
Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER, Kurie JM. Zeb1 drives pro-metastatic actin cytoskeletal remodeling by down-regulating miR-34a expression. J Clin Invest 122(9):3170-83, 2012. e-Pub 2012. PMID: 22850877.
Mishra DK, Thrall MJ, Baird BN, Ott HC, Blackmon SH, Kurie JM, Kim MP. Human lung cancer cells grown on acellular rat lung matrix create perfusable tumor nodules. Ann Thorac Surg 93(4):1075-81, 2012. e-Pub 2012. PMID: 22385822.
Mishra DK, Sakamoto JH, Thrall MJ, Baird BN, Blackmon SH, Ferrari M, Kurie JM, Kim MP. Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One 7(9):e45308, 2012. e-Pub 2012. PMID: 23028922.
Chatterjee S, Seifried L, Feigin ME, Gibbons DL, Scuoppo C, Lin W, Rizvi ZH, Lind E, Dissanayake D, Kurie JM, Ohashi P, Muthuswamy SK. Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. PLoS One 7(4):e34343, 2012. e-Pub 2012. PMID: 22529912.
Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 71(24):7670-82, 2011. e-Pub 2011. PMID: 21987723.
Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor {gamma}2 expression. Mol Cell Biol 31(21):4270-85, 2011. e-Pub 2011. PMID: 21896780.
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) 4(6):818-28, 2011. e-Pub 2011. PMID: 21636548.
Borok Z, Whitsett JA, Bitterman PB, Thannickal VJ, Kotton DN, Reynolds SD, Krasnow MA, Bianchi DW, Morrisey EE, Hogan BL, Kurie JM, Walker DC, Radisky DC, Nishimura SL, Violette SM, Noble PW, Shapiro SD, Blaisdell CJ, Chapman HA, Kiley J, Gail D, Hoshizaki D. Cell plasticity in lung injury and repair: report from an NHLBI workshop, April 19-20, 2010. Proc Am Thorac Soc 8(3):215-22, 2011. e-Pub 2011. PMID: 21653526.
Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Kurie JM. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 121(4):1373-1385, 2011. e-Pub 2011. PMID: 21403400.
Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res 9(1):25-35, 2011. e-Pub 2011. PMID: 21115742.
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-27, 2010. e-Pub 2010. PMID: 20154724.
Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 3(2):148-59, 2010. e-Pub 2010. PMID: 20103722.
Ahn YH, Kurie JM. MKK4/SEK1 is negatively regulated through a feedback loop involving the E3 ubiquitin ligase itch. J Biol Chem 284(43):29399-404, 2009. e-Pub 2009. PMID: 19737936.
Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, Kurie JM, Yen R, Evans CM, Ludwig T, Jeong JW, DeMayo FJ. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development 136(19):3347-56, 2009. e-Pub 2009. PMID: 19710174.
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23(18):2140-51, 2009. e-Pub 2009. PMID: 19759262.
Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, Pannicia C, Kurie JM, Threadgill DW. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 119(9):2702-13, 2009. e-Pub 2009. PMID: 19690388.
Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct biological roles for the notch ligands jagged-1 and jagged-2. J Biol Chem 284(26):17766-74, 2009. e-Pub 2009. PMID: 19398556.
Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ. Promotion of Lung Carcinogenesis by COPD-like Airway Inflammation in a K-ras Induced Mouse Model. Am J Respir Cell Mol Biol 40(4):443-53, 2009. e-Pub 2009. PMID: 18927348.
Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 4(4):e5401, 2009. e-Pub 2009. PMID: 19404390.
Sun H, Chung WC, Ryu SH, Ju Z, Tran HT, Kim E, Kurie JM, Koo JS. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila Pa) 1(5):316-28, 2008. e-Pub 2008. PMID: 19138976.
Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, Pandey A, Kurie JM. Identification of secreted proteins that mediate cell-cell Interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 68(17):7237-7245, 2008. e-Pub 2008. PMID: 18757440.
Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral epiregulin is a marker of advanced disease in non-Small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila Pa) 1(3):201-207, 2008. e-Pub 2008. PMID: 19138957.
Zhang L, Lee JJ, Tang H, Fan YH, Xiao L, Ren H, Kurie JM, Morice RC, Hong WK, Mao L. Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev Res (Phila Pa) 1(2):112-8, 2008. e-Pub 2008. PMID: 19138944.
Johnson EM, Price RE, Kurie JM, Rivera BS, Cody DD. A new method for respiratory gating during microcomputed tomography of lung in mice. J Am Assoc Lab Anim Sci 47(4):46-56, 2008. e-Pub 2008. PMID: 18702451.
Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila Pa) 1(1):39-44, 2008. e-Pub 2008. PMID: 19138934.
Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952-60, 2008. e-Pub 2008. PMID: 18413809.
Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, Sato M, Minna JD, Wu H, Creighton CJ, Demayo FJ, Wistuba II, Kurie JM. Pten Inactivation Accelerates Oncogenic K-ras-initiated Tumorigenesis in a Mouse Model of Lung Cancer. Cancer Res 68(4):1119-27, 2008. e-Pub 2008. PMID: 18281487.
Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 3(5):e2220, 2008. e-Pub 2008. PMID: 18493606.
Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst 99(21):1603-12, 2007. e-Pub 2007. PMID: 17971525.
Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 7(48):1-9, 2007. e-Pub 2007. PMID: 17486075.
Gray J, Mao JT, Szabo E, Kelley M, Kurie JM, Bepler G. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 132(3 Suppl):56S-68S, 2007. e-Pub 2007. PMID: 17873160.
Sethi G, Ahn KS, Xia D, Kurie JM, Aggarwal BB. Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene products. J Immunol 179(3):1926-33, 2007. e-Pub 2007. PMID: 17641059.
Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. C-Jun N-terminal Kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26(18)(18):2658-66, 2007. e-Pub 2007. PMID: 17057737.
Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFkappaB-dependent pathway. J Biol Chem 282(6):3507-19, 2007. e-Pub 2007. PMID: 17158870.
Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-76, 2007. e-Pub 2007. PMID: 17200208.
Choi K, Creighton CJ, Stivers D, Fujimoto N, Kurie JM. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One 2(11):1-11, 2007. e-Pub 2007. PMID: 18030354.
Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J 395(3):653-62, 2006. e-Pub 2006. PMID: 16417524.
Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66(8):4198-207, 2006. e-Pub 2006. PMID: 16618742.
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65(24):11478-85, 2005. e-Pub 2005. PMID: 16357156.
Mann KK, Padovani AM, Guo Q, Colosimo AL, Lee HY, Kurie JM, Miller WH. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. J Clin Invest 115(10):2924-33, 2005. e-Pub 2005. PMID: 16184197.
Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM. Murine lung tumor measurement using respiratory-gated micro-computed tomography. Invest Radiol 40(5):263-9, 2005. e-Pub 2005. PMID: 15829823.
Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65(8):3226-35, 2005. e-Pub 2005. PMID: 15833854.
Han JY, Liu DD, Lee JJ, Kurie JM, Lotan R, Hong WK, Lee HY. 9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. Clin Cancer Res 11(6):2305-11, 2005. e-Pub 2005. PMID: 15788681.
Srinivas H, Juroske DM, Kalyankrishna S, Cody DD, Price RE, Xu XC, Narayanan R, Weigel NL, Kurie JM. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol 25(3):1054-69, 2005. e-Pub 2005. PMID: 15657432.
Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65(1):226-35, 2005. e-Pub 2005. PMID: 15665299.
Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64(24):9027-34, 2004. e-Pub 2004. PMID: 15604268.
Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Jr, Pisters KM, Glisson BS, Kurie JM, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 2004. e-Pub 2004. PMID: 15050312.
Lee HY, Suh YA, Kosmeder JW, Pezzuto JM, Hong WK, Kurie JM. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res 10(3):1074-9, 2004. e-Pub 2004. PMID: 14871987.
Cavanaugh D, Johnson E, Price RE, Kurie JM, Travis EL, Cody DD. In vivo respiratory-gated micro-CT imaging in small-animal oncology models. Mol Imaging 3(1):55-62, 2004. e-Pub 2004. PMID: 15142412.
Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 2003. e-Pub 2003. PMID: 12886869.
Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 2003. e-Pub 2003. PMID: 14596703.
Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12(7):660-4, 2003. e-Pub 2003. PMID: 12869408.
Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 2003. e-Pub 2003. PMID: 12714585.
Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res 9(6):2085-91, 2003. e-Pub 2003. PMID: 12796372.
Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 95(3):206-14, 2003. e-Pub 2003. PMID: 12569142.
Soria JC, Xu X, Liu DD, Lee JJ, Kurie JM, Morice RC, Khuri F, Mao L, Hong WK, Lotan R. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 95(2):165-8, 2003. e-Pub 2003. PMID: 12529350.
Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. e-Pub 2003. PMID: 12538456.
Lee HY, Suh YA, Lee JI, Hassan KA, Mao L, Force T, Gilbert BE, Jacks T, Kurie JM. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res 8(9):2970-5, 2002. e-Pub 2002. PMID: 12231543.
Li D, Zimmerman TL, Thevananther S, Lee HY, Kurie JM, Karpen SJ. Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent. J Biol Chem 277(35):31416-22, 2002. e-Pub 2002. PMID: 12105223.
Rizvi NA, Marshall JL, Ness E, Hawkins MJ, Kessler C, Jacobs H, Brenckman WD, Lee JS, Petros W, Hong WK, Kurie JM. Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol 20(16):3522-32, 2002. e-Pub 2002. PMID: 12177113.
Suh YA, Lee HY, Virmani A, Wong J, Mann KK, Miller WH, Gazdar A, Kurie JM. Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res 62(14):3945-9, 2002. e-Pub 2002. PMID: 12124324.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 2002. e-Pub 2002. PMID: 12124835.
Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62(12):3530-7, 2002. e-Pub 2002. PMID: 12068000.
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8(5):1178-84, 2002. e-Pub 2002. PMID: 12006535.
Hastürk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 94(4):1023-31, 2002. e-Pub 2002. PMID: 11920472.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie JM, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-9, 2002. e-Pub 2002. PMID: 11917284.
Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun SY, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK, Mao L. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93(16):1257-63, 2001. e-Pub 2001. PMID: 11504771.
Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY, Broxson A, Hong WK, Hittelman WN. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst 93(14):1081-8, 2001. e-Pub 2001. PMID: 11459869.
Gazdar AF, Zöchbauer-Möller S, Virmani A, Kurie JM, Minna JD, Lam S. RESPONSE: Re: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 93(1):67-68, 2001. e-Pub 2001. PMID: 11136850.
Lee HY, Suh YA, Robinson MJ, Clifford JL, Hong WK, Woodgett JR, Cobb MH, Mangelsdorf DJ, Kurie JM. Stress pathway activation induces phosphorylation of retinoid X receptor. J Biol Chem 275(41):32193-9, 2000. e-Pub 2000. PMID: 10938283.
Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 275(43):33607-13, 2000. e-Pub 2000. PMID: 10874028.
Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19(38):4432-6, 2000. e-Pub 2000. PMID: 10980619.
Sueoka N, Lee HY, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 inhibits the growth of human bronchial epithelial cells and increases in abundance with all-trans-retinoic acid treatment. Am J Respir Cell Mol Biol 23(3):297-303, 2000. e-Pub 2000. PMID: 10970819.
Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6(8):2973-9, 2000. e-Pub 2000. PMID: 10955773.
Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie JM, Walsh GL, Truong M, Shin DM. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 18(3):243-5, 2000. e-Pub 2000. PMID: 10958592.
Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7(4):530-6, 2000. e-Pub 2000. PMID: 10811470.
Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18(3):609-22, 2000. e-Pub 2000. PMID: 10653876.
Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 59(19):4798-803, 1999. e-Pub 1999. PMID: 10519387.
Sueoka N, Lee HY, Walsh GL, Hong WK, Kurie JM. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. Cancer Res 59(15):3838-44, 1999. e-Pub 1999. PMID: 10447003.
Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17(8):2309-15, 1999. e-Pub 1999. PMID: 10561292.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9):763-71, 1999. e-Pub 1999. PMID: 10328106.
Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Mol Cell Biol 19(3):1973-80, 1999. e-Pub 1999. PMID: 10022884.
Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, Hong WK, Lotan R. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer Res 5(2):431-7, 1999. e-Pub 1999. PMID: 10037194.
Kurie JM, Lee JS, Morice RC, Walsh GL, Khuri FR, Broxson A, Ro JY, Franklin WA, Yu R, Hong WK. Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst 90(13):991-5, 1998. e-Pub 1998. PMID: 9665147.
Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25(3 Suppl 8):33-7, 1998. e-Pub 1998. PMID: 9704675.
Lee HY, Chaudhary J, Walsh GL, Hong WK, Kurie JM. Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells. Oncogene 16(23):3039-46, 1998. e-Pub 1998. PMID: 9662337.
Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 4(5):1345-55, 1998. e-Pub 1998. PMID: 9607596.
Lee HY, Dohi DF, Kim YH, Walsh GL, Consoli U, Andreeff M, Dawson MI, Hong WK, Kurie JM. All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway. J Clin Invest 101(5):1012-9, 1998. e-Pub 1998. PMID: 9486971.
Lee HY, Walsh GL, Dawson MI, Hong WK, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways. J Biol Chem 273(12):7066-71, 1998. e-Pub 1998. PMID: 9507016.
Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie JM, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys 40(2):331-6, 1998. e-Pub 1998. PMID: 9457817.
Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie JM, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs 16(3):237-43, 1998. e-Pub 1998. PMID: 10360603.
Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman WN, Hong WK. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89(12):857-62, 1997. e-Pub 1997. PMID: 9196251.
Han GR, Dohi DF, Lee HY, Rajah R, Walsh GL, Hong WK, Cohen P, Kurie JM. All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem 272(21):13711-6, 1997. e-Pub 1997. PMID: 9153223.
Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 89(9):624-9, 1997. e-Pub 1997. PMID: 9150186.
Lee HY, Dawson MI, Claret FX, Chen JD, Walsh GL, Hong WK, Kurie JM. Evidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cells. Cell Growth Differ 8(3):283-91, 1997. e-Pub 1997. PMID: 9056670.
Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ, Hong WK. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2(10):1787-93, 1996. e-Pub 1996. PMID: 9816131.
Lee HY, Dawson MI, Walsh GL, Nesbitt JC, Eckert RL, Fuchs E, Hong WK, Lotan R, Kurie JM. Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ 7(8):997-1004, 1996. e-Pub 1996. PMID: 8853895.
Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14(2):503-13, 1996. e-Pub 1996. PMID: 8636764.
Kurie JM, Lee JS, Griffin T, Lippman SM, Drum P, Thomas MP, Weber C, Bader M, Massimini G, Hong WK. Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin Cancer Res 2(2):287-93, 1996. e-Pub 1996. PMID: 9816171.
Y-H K, Dohi DF, C-P Z, Oridate N, Walsh GL, Nesbit JC, X-C X, Hong WK, Lotan R, Kurie JM. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. Cancer Res 55:5603-5610, 1995. e-Pub 1995.
Kurie JM, Allopenna J, Dmitrovsky E. Retinoic acid stimulates protein kinase A-associated G proteins during human teratocarcinoma differentiation. Biochim Biophys Acta 1222(1):88-94, 1994. e-Pub 1994. PMID: 8186270.
Miller WH, Jr, Maerz WJ, Kurie JM, Moy D, Baselga J, Lucas DA, Grippo JF, Masui H, Dmitrovsky E. All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas. Differentiation 55(2):145-52, 1994. e-Pub 1994. PMID: 8143931.
Kurie JM, Younes A, Miller WH, Burchert M, Chiu CF, Kolesnick R, Dmitrovsky E. Retinoic acid stimulates the protein kinase C pathway before activation of its beta-nuclear receptor during human teratocarcinoma differentiation. Biochim Biophys Acta 1179(2):203-7, 1993. e-Pub 1993. PMID: 8218362.
Kurie JM, Buck J, Eppinger TM, Moy D, Dmitrovsky E. 9-cis and all-trans retinoic acid induce a similar phenotype in human teratocarcinoma cells. Differentiation 54(2):123-9, 1993. e-Pub 1993. PMID: 8243889.
Kurie JM, Brown P, Salk E, Scheinberg D, Birrer M, Deutsch P, Dmitrovsky E. Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. Differentiation 54(2):115-22, 1993. e-Pub 1993. PMID: 8243888.
Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie JM, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl):2379-85, 1993. e-Pub 1993. PMID: 7683573.
Rusch VW, Reuter VE, Kris MG, Kurie JM, Miller WH, Jr, Nanus DM, Albino AP, Dmitrovsky E. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg 104(5):1465-9, 1992. e-Pub 1992. PMID: 1331621.
Kurie JM, Morse HC, Principato MA, Wax JS, Troppmair J, Rapp UR, Potter M, Mushinski JF. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice. Oncogene 5(4):577-82, 1990. e-Pub 1990. PMID: 2183159.
Troppmair J, Huleihel M, Cleveland J, Mushinski JF, Kurie JM, Morse HC, rd, Wax JS, Potter M, Rapp UR. Plasmacytoma induction by J series of v-myc recombinant retroviruses: evidence for the requirement of two (raf and myc) oncogenes for transformation. Curr Top Microbiol Immunol 141:110-4, 1988. e-Pub 1988. PMID: 3215044.

Invited Articles

Yamauchi M, Barker TH, Gibbons DL, Kurie JM. The Fibrotic Tumor Stroma. J Clin Invest 128(1):16-25, 2018. e-Pub 2018. PMID: 29293090.
Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Molecular Cancer Research 12(1):3-13, 2015. e-Pub 2015. PMID: 24442106.
Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res 12(1):3-13, 2014. e-Pub 2014. PMID: 24442106.
Settleman J, Kurie JM. Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer. Cancer Cell 12(1):6-8, 2007. e-Pub 2007. PMID: 17613432.
Haigis KM, Wistuba II, Kurie JM. Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Genes Dev 21(4):361-366, 2007. e-Pub 2007. PMID: 17322395.
Minna JD, Kurie JM, Jacks T. A big step in the study of small cell lung cancer. Cancer Cell 4(3):163-6, 2003. e-Pub 2003. PMID: 14522249.
Khuri FR, Kurie JM. Antisense approaches enter the clinic. Clin Cancer Res 6(5):1607-10, 2000. e-Pub 2000. PMID: 10815875.
Kurie JM. The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 11(6)(6):497-502, 1999. e-Pub 1999. PMID: 10550014.
Kurie JM, Hong WK. Retinoids as antitumor agents: a new age of biological therapy. Cancer J Sci Am 5(3):150-1, 1999. e-Pub 1999. PMID: 10367170.

Review Articles

Tan X, Xiao GY, Banerjee P, Wang S, Kurie JM. The cancer-associated secretory phenotype: a new frontier in targeted therapeutics. J Clin Invest 134(17), 2024. e-Pub 2024. PMID: 39225096.
Kurie JM. Role of protein kinase B-dependent signaling in lung tumorigenesis. Chest 125(5 Suppl):141S-4S, 2004. e-Pub 2004. PMID: 15136468.

Editorials

Kurie JM. Cyclin D1 expression in the field of exposure: another piece in the molecular Auerbach puzzle. J Clin Oncol 21(11):2056-8, 2003. PMID: 12775729.
Kurie JM, Dubois RN. Prostaglandin E synthase: another enzyme in the cyclooxygenase pathway driving epithelial cancer?. Clin Cancer Res 7(9):2608-10, 2001. PMID: 11555570.

Abstracts

Guo H, Chen Y, Banerjee P, Tan X, Bota-Rabassedas N, Byemerwa J, Alvarado S, Terajima M, Yamauchi M, Creighton C J, Phillips Jr GN, Kurie JM. Structural insights into a collagen galactosylhydroxylysine glucosyltransferase. Keystone Symposium on Injury, Inflammation and Fibrosis (C8), 2017. e-Pub 2017.
Banerjee P, Tan X, Kurie JM. A confocal super-resolution approach to study the dynamics of golgi apparatus in lung cancer metastasis. 61st Annual meeting of the Biophysical Society, 2017. e-Pub 2017.
Bota N, Banerjee P, Albritton J, Rodriguez J, Weiger M, Liu X, Mino B, Lammoglia G, Kinstlinger I, Calafat N, Gibbons D, Wistuba I, Liphardt J, Miller J, Kurie JM. A 3D co-culture model to elucidate the molecular basis for interactions between cancer-associated fibroblasts and lung adenocarcinoma cells that drive early metastasis. Keystone Symposia: Cellular Plasticity in the Tumor Microenvironment, 2017. e-Pub 2017.
Banerjee P, Tan X, Kurie JM. A confocal super-resolution approach to study the dynamics of golgi apparatus in lung cancer metastasis. 2017 Quantitative BioImaging Conference, 2017. e-Pub 2017.
Byemerwa J, Guo HF, Kurie JM. A Novel High-throughput Assay for Characterization of a Pro-metastatic Collagen Lysyl Hydroxylase 2 Activity. Annual Biomedical Research Conference for Minority Students, 2016. e-Pub 2016.
Bota N, Banerjee P, Albritton J, Rodriguez J, Weiger M, Liu X, Mino B, Lammoglia G, Kinstlinger I, Calafat N, Gibbons D, Wistuba I, Liphardt J, Miller J, Kurie JM. A 3D co-culture model to elucidate the molecular basis for interactions between cancer-associated fibroblasts and lung adenocarcinoma cells that drive early metastasis. European Molecular Biology Laboratory Symposium:Organoids: Modelling organ development and disease in 3D culture, 2016. e-Pub 2016.
Bota N, Albritton J, Weiger M, Rodriguez J, Grzeskowiak C, Best E, Calafat N, Scott K, Miller J, Kurie JM. A 3D co-culture model to elucidate the molecular basis for interactions between cancer-associated fibroblasts and lung adenocarcinoma cells that drive early metastasis. Keystone Symposia Meeting - Fibrosis: From Basic Mechanisms to Targeted Therapies Q3, 2016. e-Pub 2016.
Guo H, Chen Y, Alvarado S, Terajima M, Yamauchi M, Cho EJ, Dalby K, Phillips Jr GN, Kurie JM. Structural insights into a pro-metastatic collagen lysyl hydroxylase. Keystone Symposia: Fibrosis: From Basic Mechanisms to Targeted Therapies (Q3) Q3, 2016. e-Pub 2016.
Best EK, Caneles-Rodriguez J, Kurie JM. Foxd1+Fibroblasts active in pulmonary fibrosis are recruited as cancer associated fibroblasts in lung adenocarcinoma. Keystone Symposia Meeting - Fibrosis: From Basic Mechanisms to Targeted Therapies, 2016. e-Pub 2016.
Chen Y, Terajima M, Rodriguez J, Wistuba II, Yamauchi M, Kurie JM. FKBP65 regulates LH2 function through its prolyl isomerase actvity. Keystone Symposia Meeting - Fibrosis: From Basic Mechanisms to Targeted Therapies, 2016. e-Pub 2016.
Tan X, Banerjee P, Kurie JM. ZEB1-microRNA axes control a Golgi polarization switch that regulates cell migration. Keystone Symposium - MicroRNAs and Noncoding RNAs in Cancer (E5) E5, 2015. e-Pub 2015.
Roybal JD, Yi Z, Gibbons DL, Lin W, Alvarez C, Thilaganathan N, Tran H, Kurie JM. Development of an in vitro model to study tumor cell-fibroblast interactions. Keystone Symposia: Role of Inflammation in Oncogensis J5, 2011. e-Pub 2011.
Roybal JD, Baird BN, Alvarez C, Thilaganathan N, Gibbons DL, Kurie JM. The magic is in the matrix: Using nature’s architectural platform to treat lung cancer tumorigenesis and metastasis. Keystone Symposia: Extracellular Matrix and Cardiovascular Remodeling B2, 2011. e-Pub 2011.
Ahn YH, Gibbons DL, Creighton CJ, Kurie JM. miR-34a inhibits tumorigenesis and metastasis by targeting TGFbeta-induced Rho/Rac/Cdc42 activation. Keystone Symposium: Extracellular Matrix and Cardiovascular Remodeling (B2) B2, 2011. e-Pub 2011.
Ahn YH, Yang Y, Gibbons DL, Lin W, Thilaganathan N, Creighton CJ, Goldsmith EJ, Kurie JM. MAP2K4 loss-of-function promotes cancer cell invasion. Keystone Symposia: Metabolism and Cancer Progression X4, 2010. e-Pub 2010.
Zhong L, Roybal J, Chaerkady R, Choi K, Tran H, Strieter RM, Pandey A, Kurie JM. Lung stromal cells enhance the local concentrations of Tumorigenic chemokines and cytokines through tumor/stromal and stromal/stromal interactions. Keystone Symposia: Extrinsic Control of Tumor Genesis and Progression, 2009. e-Pub 2009.
Zhong L, Roybal JD, Choi K, Tran H, Strieter RM, Kurie JM. Mechanism of stromal cell chemoattraction in cellular models of mouse lung adenocarcinoma. Keystone Symposia: Extrinsic Control of Tumor Genesis and Progression C8, 2009. e-Pub 2009.
Zhong L, Roybal JD, Chaekady R, Choi K, Tran H, Strieter RM, Pandey A, Kurie JM. Lung stromal cells enhance the local concentrations of tumorigenic chemokines and cytokines through tumor/stromal and stromal/stromal interactions. Keystone Symposia: Inflammation, Microenvironment and Cancer D2, 2008. e-Pub 2008.
Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Burdick MD, Sato Mitsuo S, Minna JD, Wistuba I, Strieter RM, Kurie JM. Role of the Tumor Microenvironment in the Promotion of Alveolar Epithelial Neoplasia Induced by Oncogenic KRAS. Keystone Symposia: Inflammation, Microenvironment and Cancer, 2008. e-Pub 2008.
Iwanaga K, Hanna AE, Wu H, Demayo FJ, and Kurie JM. Creation of mouse models of human lung cancer by activation of P13K/AKT-dependent signaling 47:1201, 2006. e-Pub 2006.
Erminia M, Zhou X, Ozburn NC, Wislez M, Bekele BN, Roth JA, O’Reilly M, Hong WK, and Kurie JM. TGF-α and phosphorylated EGFR protein levels impact the survival of patients with stage I-IIIA non small cell lung cancer 47:1348, 2006. e-Pub 2006.
Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Burdick MD, Sato M, Minna JD, Wistuba I, Streiter RM, Kurie JM. Role of the tumor microenvironment in the promotion of alveolar epithelial neoplasia induced by oncogenic KRAS, 2006. e-Pub 2006.
Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Burdick MD, Sato M, Minna JD, Wistuba I, Streiter RM, and Kurie JM. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic Kras. signal transduction by engineered extracellular matrices 47:67, 2006. e-Pub 2006.
Cai D, Shames DS, Girard L, Peyton M, Sato M, Gao B, Ashimi S, Fujimoto N, Wistuba I, Kurie JM, Lam C, Wong MP, Gerald WL, Gazdar AF, and Minna JD. Lung cancers express high levels of EGF family ligands in expression patterns that correlate with the presence of mutations in the MAPK pathway 47:306, 2006. e-Pub 2006.
Zhang J, Kalyankrishna S, Johnson FM, and Kurie JM. Src is constitutively activated in non-small cell lung cancer cells with mutant epidermal growth factor recptor and contributes to cell survival 47:40, 2006. e-Pub 2006.
Peyton MJ, Girard L, Gao B, Shames D, Ellahi A, Kurie JM, Gazdar A, and Minna JD. Molecular markers for determining Gefitinib sensitivity 47:300, 2006. e-Pub 2006.
Fujimoto N, Wislez M, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu DD, Cody DD, Wistuba II, and Kurie JM. Suppression of KRAS-induced lung prneoplasia by inhibition of the Met receptor tyrosine kinase 47:416, 2006. e-Pub 2006.
Khatlani TS, Sliger A, and Kurie JM. Mitogen-activated protein kinase kinase-4 is activated in non-small cell lung cancer and confers neoplastic properties through c-Jun N-terminal kinase-dependent and -independent mechanisms 47:623, 2006. e-Pub 2006.
Kawashima H, Uno F, Kurie JM, Minna JD, Roth JA, and Ji L. Synergistic inhibition of EGFR tyrosine kinase activity and NSCLC cell growth by combination treatment with FUS1-nanoparticle and gefitinib 46:637, 2005. e-Pub 2005.
Zhang L, Lee J, Tang H, Fan Y, Ziao L, Ren H, Kurie JM, Morice RC, Hong WK, and Mao L. Impact of smoking cessation on global gene expression in bronchial epithelium of chronic smokers 46:207, 2005. e-Pub 2005.
Fujimoto N, Wislez M, Juroske D, Sliger A, Cody DD, Threadgill D, and Kurie JM. EGFR inhibition reverses alveolar epithelial cell preneoplasia induced by oncogenic K-ras 46:1429, 2005. e-Pub 2005.
Mao L, Zhang L, Lee JJ, Tang H, Fan Y, Xiao L, Kurie JM, Morice RC, and Hong WK. Global change of gene expression profile after 3 month administration of celecoxib, a COX-2 selected inhibitor, in bronchial epithelium of chronic smokers 46:1042, 2005. e-Pub 2005.
Kalyankrishna S, Zhang J, Johnson F, and Kurie JM. Ligand-independent activation of mutant EGFR in lung cancer cells: Enhanced sensitivity to c-Src tyrosine kinase inhibitors 46:1020, 2005. e-Pub 2005.
Mann KK, Padovani AMS, Lee H, Kurie JM, WH Jr AM. Arsenic trioxide inhibits nuclear receptor function of RXR-containing heterodimers 46:949, 2005. e-Pub 2005.
Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara KB, Liu DD, Cody D, Price RE, Hittelman W, Wistuba II, and Kurie JM. mTOR inhibition reverses alveolar epithelial neoplasia induced by oncogenic K-ras through macrophage apoptosis 46:612, 2005. e-Pub 2005.
Wislez M, Wistuba I, Juroske D, Bekele N, Cody D, Price R, Kurie JM. CCI-779 has anti-tumor activity in K-rasLA1 mice, a model of human lung bronchioloalveolar carcinoma. 12th SPORE Investigator’s Workshop Meeting, Baltimore, Maryland 189:186, 2004. e-Pub 2004.
Wislez M, Wistuba I, Juroske D, Bekele N, Cody D, Price R, Kurie JM. CCI-779 has anti-tumor activity in K-rasLA1 mice, a model of human lung bronchioloalveolar carcinoma 189:186, 2004. e-Pub 2004.
Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, and Kurie JM. Activation of phosphatidylinositol 3-kinase-dependent signaling in bronchial premalignancy and non-small lung cancer 44:661, 2004. e-Pub 2004.
Srinivas H, Kurie JM. Ligand-independent degradation of retinoic acid receptor alpha through phosphorylation by stress kinases 44:541, 2004. e-Pub 2004.
Mao L, Fan YH, Kurie JM, Lee JJ, Morice R, and Hong WK. Promoter hypermethylation in bronchial epithelial cells of smokers and effect of retinoids, 2004. e-Pub 2004.
Tsao A, Zhou X, McDonnell T, Putnam JB, Bekele N, Hong WK, and Kurie JM. Smoking does not correlate with pAKT expression in NSCLC, 2004. e-Pub 2004.
Xia D, LaPushin R, Mills GB, Kurie JM. PI3K/AKT- and MKK4/JNK-dependent pathways cooperate to maintain cell survival. Proc AACR 341:5011, 2004. e-Pub 2004.
Srinivas H, Juroske DM, Cody DD, Price RE, Xu X, Narayanan R, Weigel NL, Kurie JM. Stress contributes to aberrant retinoid signaling in lung cancer cells through cJun N-terminal kinase, which phosphorylates and induces proteasomal degradation of retinoic acid receptor-alpha. Proc AACR 73:259, 2004. e-Pub 2004.
Kalyankrishna S, Kurie JM. Regulation of epidermal growth factor receptor signaling during lung tumorigenesis. Proc AACR 71:173:173, 2004. e-Pub 2004.
Xia D, Juroske D, Mills, G, Kurie, JM. KP-372-1, a potent AKT inhibitor, induces apoptosis of NSCLC cell lines. 11th SPORE Investigators Workshop Meeting, Baltimore, Maryland, 2003. e-Pub 2003.
Lee HY, Srinivas H, Lu Y, Lapushin R, Force T, Mills G, Kurie JM. p85a stimulates lung cancer cell proliferation and survival through activation of phosphoinositide 3-kinase and RAC-1 dependent pathways. Proc AACR 15:302, 2002. e-Pub 2002.
Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. A study of COX 1 and COX 2 expression in bronchial epithelium and non-small cell lung cancers. Proc ASCO 40:429, 2001. e-Pub 2001.
Young AS, Lee HY, Hong WK, Kurie JM. The regulation of retinoic acid receptor b (RARb) in lung cancer cell lines. Proc AACR 42:322, 2001. e-Pub 2001.
Suh YS, Lee HY, Hong WK, Kurie JM. The regulation of retinoic acid receptor beta (RARb) in lung cancer cell lines. Keystone Symposia Signaling Systems: Chemistry, Biology and Pathology E4:68, 2001. e-Pub 2001.
Soria JC, Moon C, Wang L, Jang SJ, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK, Mao L. Down-regulations of TERT expression in bronchialepithelium of smokers by N-(4hydroxyphenyl) retinamide. Proc AACR 42:825, 2001. e-Pub 2001.
Lee JS, Lotan R, Mao L, Lee JJ, Kurie JM, Xu X, Liu D, Morice R, Ro J, Hittleman W, Hong WK. Association of LOH and loss of RAR-b expression in bronchial epithelium with prior history of smoking-related cancer: A marker for high-risk group. Proc AACR 42:3988, 2001. e-Pub 2001.
Lee HY, Wiehle S, Cristiano R, Fang, BL, Ji L, Roth J, Hong WK, Kurie JM. The effects of insulin-like growth factor binding protein-3 on lung cancer. Proc AACR 42:405, 2001. e-Pub 2001.
Kurie, JM, Khuri F, Ibarguen H, Mao L, Morice RC, Walsh G, Ro JY, Hong WK, Lee JJ. The influence of chronic tobacco exposure and smoking cessation on proliferation in bronchial epithelium. Proc AACR 42:827, 2001. e-Pub 2001.
Kurie JM, Young AS, Lee HY, Hong WK. Studies to restore the retinoic acid response in ling cancer cell lines. Proc AACR 41:14, 2000. e-Pub 2000.
Squeak N, Lee HY, Walsh GL, Fang B, Jib L, Roth A, capuchin R, Hong WK, Curie JM. Role of insulin-like growth factor binding protein-6 in the proliferation of human bronchial epithelial cells and non-small cell lung cancer cell lines. Proc AACR 41:500, 2000. e-Pub 2000.
Lee HY, Walsh G, Hong WK, Kurie JM. Lung cancer chemoprevention induced by deguelin, a novel COX2 inhibitor. Proc AACR 41:856, 2000. e-Pub 2000.
Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual specificity phosphates activity. Proc ASCO 40:60, 1999. e-Pub 1999.
Kurie JM, Lee JS, Khuri FR, Morice RC, Walsh GL, Broxson A, Ro JY, Kemp BL, Lee JJ, Lotan R, Xu X, Lu D, Hong WK. 4-Hydroxyphenylretinamide (4-HPR) in the reversal of bronchial metaplasia and dysplasia in smokers. Proc ASCO 16:473a, 1999. e-Pub 1999.
Sueoka N, Lee HY, Walsh GL, Hong WK, JMa K. Proliferative arrest of human bronchial epithelial cells by all-trans retinoic acid involves increased expression of the CDK inhibitor p27 and reduced expression and activity of specific cyclin:CDK complexes. Proc Amer Assoc Cancer Res 40:308, 1999. e-Pub 1999.
Hittelman WN, Lee JS, Morice RC, Kurie JM, Khuri F, Ibarguen H, Corrales C, Ro JY, Kemp B, Broxson A, Liu D, Lee JJ, Hong WK. Lack of biomarker modulation in bronchial biopsies of chronic smokers following treatment with N-(4-hydroxyphenyl) retinimide. Proc Amer Assoc Cancer Res 40:429, 1999. e-Pub 1999.
Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler, Liu D, Munden R, Hong, WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated non-small cell lung cancer. Proc ASCO 16:462a, 1999. e-Pub 1999.
Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. A study of COX 1 and COX 2 expression in bronchial epithelium and non-small cell lung cancers. Proc Amer Assoc Cancer Res 40:429, 1999. e-Pub 1999.
Morice RC, Lee JS, Kurie JM, Khuri FR, Ro JY, Kemp BL, Broxson A, Liu D, Hong WK. Bronchial squamous metaplasia and dysplasia in current and former smokers. Proc ASCO 16:472a, 1999. e-Pub 1999.
Lee HY, Walsh G, Marcia D, Hong WK, Kurie JM. All-trans retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways. Proc Amer Assoc Cancer Res 39:275, 1998. e-Pub 1998.
Sueoka N, Lee HY, Rajah R, Walsh G, Hong WK, Cohen P, Kurie JM. The role of insulin-like growth factor binding proteins in retinoids signaling. Proc Amer Assoc Cancer Res 39:111, 1998. e-Pub 1998.
Hittelman WN, Yu R, Kurie JM, Lee JS, Morice RC, Walsh GL, Ro JY, Hong WK, Lee JJ. Evidence for genomic instability and clonal outgrowth in the bronchial epithelium of smokers. Proc Am Assoc Cancer Res 38:463, 1997. e-Pub 1997.
Swisher SG, Roth JA, Lawrence DD, Kemp BL, Carrasco CH, Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesibtt JC, Pisters KM, PutnamJB, Schrump DS, Shin DM, Walsh GL. Adenoviral-mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 16:437a, 1997. e-Pub 1997.
Swisher SG, Roth JA, Lawrence D, Kemp B, Carrasco C, Fossella F, Glisson B, Hong WK, Khuri F, Kurie JM, Nesbitt J, Pisters K, Putnam JB, Schrump D, Shin D, Walsh G. Persistent transgene expression following repeated injections of a recombinant adenovirus containing the p53 wildtype gene in patients with nonsmall cell lung cancer. Proc Am Assoc Cancer Res 38:342, 1997. e-Pub 1997.
Mao L, Lee JS, Kurie JM, Khuri FR, Fan YH, Lippman SM, Lee JJ, Ro JY, Hittelman WN, Hong WK. Frequent genetic alterations in bronchial epithelium of smokers. Proc Am Assoc Cancer Res 38:246, 1997. e-Pub 1997.
Lee HY, Hong W, Kurie JM. c-Fos expression decreases by transcriptional mechanisms during the malignant transformation of human bronchial epithelial cells. Proc Am Assoc Cancer Res 38:585, 1997. e-Pub 1997.
Kurie JM, Lee JS, Morice R, Walsh GL, Khuri FR, Broxson A, Ro J, Lippman SM, Hong WK. Auto-fluorescence bronchoscopy in the detection of bronchial metaplasia and dysplasia in chronic smokers. Proc ASCO 16:458a, 1997. e-Pub 1997.
Han GR, Dohi D, Lee HY, Walsh G, Nesbitt J, Hong W, Cohen P, Kurie JM. Retinoic acid increases insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-a-dependent, transforming growth factor-b-independent signaling pathway. Proc Am Assoc Cancer Res 38:563, 1997. e-Pub 1997.
Han GR, Dohi DF, Lee HY, Hong WK, Cohen P, Kurie JM. Retinoic acid receptor RARa-dependent signaling pathways activate expression of transforming growth factor-b2 and insulin-like growth factor binding protein-3. Proc EMBO Workshop: Structure and Function of Nuclear Receptors. Erice, Italy, 1997. e-Pub 1997.
Glisson BS, Kurie JM, Fox NJ, Murphy WK, Winn RJ, Perez-Soler R, Pisters KMW, Shin DM, Hong WK. Phase I-II study of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive small cell lung cancer (ESCLC). Proc ASCO 16:455a, 1997. e-Pub 1997.

Book Chapters

Kurie JM, Wislez M. The intersection of EGFR and the RAS signaling pathway. In: EGFR Signaling Networks in Cancer Therapy. Humana Press, 89-95, 2008.
Kurie JM, Minoo P, Hecht SS, Nikitin A, DeMayo FJ. Lung malignancies. In: Mouse Models of Cancer. Wiley Inc, 2003.
Kurie JM, Dmitrovsky E. Retinoic acid and human teratocarcinoma differentiation. In: The Pharmacology of Cell Differentiation. Elsevier Science Publishers BV, 203-216, 1996.
Kurie JM, Lippman SM, Hong WK. Chemoprevention trials: Epithelial carcinogenesis and the biological basis of intervention. In: Encyclopedia of Cancer. Academic Press Inc, 341-354, 1996.

Letters to the Editor

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proc Natl Acad Sci U S A 115: E10810-E10811, 2018.
Guo HF, Kurie J. Phenotypic Consequences of PLOD2 Mutations in Bruck Syndrome Inform a Collagen Lysyl Hydroxylase Crystal Structure. J Bone Miner Res 33: 1376, 2018.

Less

CV information above last modified March 23, 2026

Jonathan M. Kurie, MD

About Dr. Jonathan M. Kurie

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Kurie Laboratory

Thoracic/Head and Neck Medical Oncology department

Cancer Medicine division

Help #EndCancer

Jonathan M. Kurie, MD

About Dr. Jonathan M. Kurie

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Kurie Laboratory

Thoracic/Head and Neck Medical Oncology department

Cancer Medicine division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson